Market Research and Forecast Analysis of Tumor Drugs
Click:300  Update time:2022-12-16  【Close

Influenced by lifestyle, environmental degradation, social pressure and other factors, the number of cancer and metabolic diseases has been increasing in China and the world in recent years, which not only affects the research and development and production of enterprises, but also has a significant impact on the development of the entire pharmaceutical industry.


Analysis of global pharmaceutical market

The global pharmaceutical market is mainly divided into two parts: chemical medicine and biological medicine. The scale of the global pharmaceutical market in 2021 will be 1393.4 billion US dollars, and it is expected to reach 1708.4 billion US dollars by 2025, with a compound annual growth rate of about 4.4%. From the perspective of income composition, chemical drugs still account for the main part. In 2021, the global market size of chemical drugs will reach 1056.8 billion US dollars, accounting for 75.8% of the total pharmaceutical market size. It is estimated that by 2025, the global market size of chemical drugs will be about 1208.3 billion US dollars. Although the current market size of biological drugs is smaller than that of chemical drugs, which will be only 336.6 billion dollars in 2021, with the continuous breakthrough of biotechnology, biological products such as biological analogues will continue to emerge. It is estimated that the market size of biological drugs will grow to 500.1 billion dollars by 2025, with a compound annual growth rate of about 9%.


Global pharmaceutical market size from 2015 to 2025


Analysis of China's pharmaceutical market

China's pharmaceutical market is mainly divided into three parts: chemical medicine, traditional Chinese medicine and biological medicine. Among them, the scale of China's pharmaceutical market in 2021 will be 1729.2 billion yuan, which is expected to reach 2287.3 billion yuan by 2025, with a compound annual growth rate of about 4%. From the perspective of income composition, chemical drugs still occupy a large share, accounting for 48.9% of China's pharmaceutical market, while traditional Chinese medicine and biological drugs account for 26.5% and 24.6%. With the continuous breakthrough of biotechnology, biological products such as biological analogues will continue to emerge. It is estimated that by 2025, its Chinese market size will reach 811.6 billion yuan, with an annual compound growth rate of more than 10%.

2015-2025 China's pharmaceutical market size

Note: Unit: 100 million yuan


Epidemiological analysis of tumor

According to the statistics of the World Health Organization (WHO) in 2019, cancer is the first or second leading cause of death in 112 countries and the third or fourth leading cause of death in 23 countries. At present, the number of new cancer patients in the world is nearly 20 million, which is expected to reach 21 million by 2025, with a compound annual growth rate of about 2.4%. At present, the number of new cancer patients in China is about 4.5 million, which is expected to exceed 5 million by 2025, with a compound annual growth rate of 2.7%.


Number of new cases of cancer worldwide and in China from 2015 to 2025

Note: Unit: 10000 persons


The top ten cancers with incidence rate in the world are: breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, cervical cancer, esophageal cancer, thyroid cancer and bladder cancer, which account for 63% of the total number of new cancers.
In 2021, the top ten most common cancers among Chinese men and women are:
Male: prostate cancer (26%), lung cancer and bronchial cancer (12%), colorectal cancer (8%), bladder cancer (7%), melanoma (6%), renal cancer (5%), non Hodgkin's lymphoma (5%), oral cancer (4%), leukemia (4%), and pancreatic cancer (3%).
Women: breast cancer (30%), lung cancer and bronchial cancer (13%), colorectal cancer (8%), endometrial cancer (7%), melanoma (5%), non Hodgkin's lymphoma (4%), thyroid cancer (3%), pancreatic cancer (3%), renal cancer (3%), leukemia (3%).
In 2021, the top ten cancers with mortality among Chinese men and women will be:
Male: lung cancer (22%), prostate cancer (11%), colorectal cancer (9%), pancreatic cancer (8%), liver cancer (6%), leukemia (4%), esophageal cancer (4%), bladder cancer (4%), non Hodgkin's lymphoma (4%), brain tumor (3%).
Women: lung cancer (22%), breast cancer (15%), colorectal cancer (8%), pancreatic cancer (8%), ovarian cancer (5%), endometrial cancer (4%), liver cancer (3%), leukemia (3%), non Hodgkin's lymphoma (3%), brain tumor (3%).


Analysis of the global cancer drug market

From 2015 to 2021, the global market size of anti-tumor drugs will increase from US $83.2 billion to US $177.9 billion, accounting for 7.5% and 12.3% of the global drug market respectively, with a compound growth rate of about 14%. The steady growth of the market size is related to the increasing number of patients and their ability to pay for treatment. Driven by immunotherapy, the global market size of anti-tumor drugs is expected to reach 266.4 billion dollars in 2025.


lobal tumor drug market size from 2015 to 2025 (unit: 100 million US dollars,%)


Market analysis of cancer drugs in china

From 2015 to 2021, the market size of anti-tumor drugs in China will increase from 110.2 billion yuan to 244 billion dollars, showing a steady growth trend. The proportion in the Chinese drug market will also increase from 9.0% to 13.6%, with a compound growth rate of about 13.5%. The steady growth of the market size is related to the increasing number of patients and the successive approval and listing of innovative drugs. Driven by immunotherapy, the market size of anti-tumor drugs in China is expected to reach 411.2 billion yuan in 2025, and its percentage in the Chinese drug market will reach 17.3%.


Market scale of cancer drugs in China from 2015 to 2025 (unit: 100 million yuan,%)

The data and cover pictures are from Frost Sullivan's analysis and network. If there is infringement, please contact to delete

Last:Methodology of drug development based on "hypothesis verification" theoretical framework
Next:Health science popularization will be included in the evaluation of senior professional titles of health professionals in Shanghai

LINDMIK PHARMA

Lindmik Pharmaceutical(Suzhou)Co.,Ltd is a high-tech pharmaceutical enterprise focusing on the research and development, production and sales of innovative pharmaceutical preparations.Equipped with a number of its own innovative R&D platform of dosage forms, including the transdermal drug delivery system, and at the same time, actively introducing the world’s leading nano-based drug delivery, microspheres drug delivery and other cutting-edge pharmaceutical technologies by means of “license in”, the company is a new rapidly developing company pharmaceutical companies that catches people’s eyes.

SIGN UP

LINDMIK MAP

OUR CONTACT

  • 12th Floor, Building 5, Tianyun Plaza, 111 Wusongjiang Avenue, Guoxiang Street, Wuzhong District, Suzhou City

  • 0512-66020899

  • 0512-66022699

  • 215124

© COPYRIGHT Lindmik Pharmaceutical(Suzhou)Co.,Ltd. All Rights Reserved